{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T05:11:34Z","timestamp":1788757894165,"version":"build-2803163510"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>FGF21 is associated with atherosclerosis and the anatomical severity of coronary artery disease. No study has explored the relationship between FGF21 and intracranial atherosclerotic stenosis. The purpose of this study is to explore the association between FGF21 and intracranial atherosclerotic stenosis in patients with type 2 diabetes mellitus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>One hundred ten patients with type 2 diabetes were recruited. The levels of plasma FGF21 were measured by enzyme-linked immunosorbent assays. The severity of intracranial atherosclerotic stenosis was evaluated in strict accordance with the internationally recognized modified Warfarin-Aspirin Symptomatic Intracranial Disease criteria. Patients were categorized into three groups based on percent stenosis: no stenosis (0%), mild stenosis (1\u201349%), and moderate to severe stenosis (\u226550%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Plasma FGF21 level was different among no stenosis group, mild stenosis group and moderate to severe stenosis group (114.35 (105.35\u2013124.04) vs. 124.81 (118.84\u2013134.47) vs. 132.18 (120.43\u2013150.05), H\u202f=\u202f17.327,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u202f0.001). FGF21 levels in the moderate-to-severe stenosis group were higher than those in the no stenosis + mild stenosis group (132.18 (120.43\u2013150.05) vs. 122.44 (109.88\u2013129.19), U\u202f=\u202f-3.138,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.002). The highest tertile (T3) of FGF21 level (&amp;gt;129.55\u202fng\/L) and lnFGF21 was associated with moderate to severe intracranial atherosclerotic stenosis in patients with T2DM after adjusting for age and\u03b1-glucosidase inhibitor use (OR\u202f=\u202f6.453, 95% CI: 1.944\u201321.415,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.002; OR\u202f=\u202f2.191, 95% CI: 1.277\u20133.759,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.004). Based on the receiver-operating characteristic (ROC) curve, the combination of lnFGF21, age, and \u03b1-glucosidase inhibitor use predicted moderate to severe intracranial atherosclerotic stenosis in patients with type 2 diabetes mellitus, with an area under the curve (AUC) of 0.768 (95% CI, 0.670\u20130.865). Bootstrap resampling with 1,000 replicates was performed for internal validation to assess model stability and calibration (bootstrap B\u202f=\u202f1,000; MAE\u202f=\u202f0.021, MSE\u202f=\u202f0.00064, 90th percentile of absolute error\u202f=\u202f0.038).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We observed a significant cross-sectional association between plasma FGF21 levels and intracranial atherosclerotic stenosis among patients with T2DM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1904036","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T04:23:45Z","timestamp":1788755025000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma FGF21 is associated with intracranial atherosclerotic stenosis in patients with type 2 diabetes mellitus"],"prefix":"10.3389","volume":"17","author":[{"given":"Qiongzhang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenjing","family":"Xie","sequence":"additional","affiliation":[{"name":"School of Mental Health, Wenzhou Medical University","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Mental Health, Wenzhou Medical University","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengwei","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Mental Health, Wenzhou Medical University","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Kong","sequence":"additional","affiliation":[{"name":"School of Mental Health, Wenzhou Medical University","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc25-S002","article-title":"Diagnosis and classification of diabetes: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1161\/CIRCULATIONAHA.110.014506","article-title":"Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus","volume":"124","author":"Shenouda","year":"2011","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.120.046464","article-title":"Hyperglycemia induces trained immunity in macrophages and their precursors and promotes atherosclerosis","volume":"144","author":"Edgar","year":"2021","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12933-025-03060-5","article-title":"Activator protein-1 (AP-1) inhibition prevents endothelial to mesenchymal transition in diabetes-associated atherosclerosis: a translational study","volume":"25","author":"Khan","year":"2026","journal-title":"Cardiovasc Diabetol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"107605","DOI":"10.1016\/j.jdiacomp.2020.107605","article-title":"Hyperglycemia, duration of diabetes, and intracranial atherosclerotic stenosis by magnetic resonance angiography: the ARIC-NCS study","volume":"34","author":"Fujiyoshi","year":"2020","journal-title":"J Diabetes Complicat"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e106623","DOI":"10.1371\/journal.pone.0106623","article-title":"Long-term risk of cardiovascular disease among type 2 diabetic patients with asymptomatic intracranial atherosclerosis: a prospective cohort study","volume":"9","author":"Duan","year":"2014","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41569-023-00877-z","article-title":"Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention","volume":"20","author":"Wong","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/CIR.0000000000001303","article-title":"2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"151","author":"Martin","year":"2025","journal-title":"Circulation"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1111\/ene.15418","article-title":"Glucose-6-phosphate dehydrogenase deficiency and intracranial atherosclerotic stenosis in stroke patients","volume":"29","author":"Li","year":"2022","journal-title":"Eur J Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/STROKEAHA.123.043633","article-title":"Optimal medical management of atherosclerotic intracranial stenosis","volume":"55","author":"Wabnitz","year":"2024","journal-title":"Stroke"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S1474-4422(21)00376-8","article-title":"Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment","volume":"21","author":"Gutierrez","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.jacc.2021.05.041","article-title":"Determinants and outcomes of asymptomatic intracranial atherosclerotic stenosis","volume":"78","author":"Gutierrez","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"17474930261419812","DOI":"10.1177\/17474930261419812","article-title":"Chinese guidelines for diagnosis and treatment of intracranial atherosclerotic stenosis","volume":"22","author":"Leng","year":"2026","journal-title":"Int J Stroke"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e001164","DOI":"10.1136\/bmjno-2025-001164","article-title":"Intracranial atherosclerotic stenosis in Asia: a systematic scoping and rapid review of prevalence, frequency in ischaemic stroke and risk factors","volume":"7","author":"Navarro","year":"2025","journal-title":"BMJ Neurol Open"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1136\/jnnp-2020-325630","article-title":"Intracranial arterial stenosis in Caucasian versus Chinese patients with TIA and minor stroke: two contemporaneous cohorts and a systematic review","volume":"92","author":"Leng","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1220426","DOI":"10.3389\/fendo.2023.1220426","article-title":"Fibroblast growth factor 21 in metabolic syndrome","volume":"14","author":"Yang","year":"2023","journal-title":"Front Endocrinol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1159127","DOI":"10.3389\/fendo.2023.1159127","article-title":"Total serum FGF-21 levels positively relate to visceral adiposity differently from its functional intact form","volume":"14","author":"Crudele","year":"2023","journal-title":"Front Endocrinol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"115928","DOI":"10.1016\/j.bcp.2023.115928","article-title":"Berberine protects mice against type 2 diabetes by promoting PPARgamma-FGF21-GLUT2-regulated insulin sensitivity and glucose\/lipid homeostasis","volume":"218","author":"Chen","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"116042","DOI":"10.1016\/j.bcp.2024.116042","article-title":"Prolonged FGF21 treatment increases energy expenditure and induces weight loss in obese mice independently of UCP1 and adrenergic signaling","volume":"221","author":"Stanic","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3724\/abbs.2024032","article-title":"FGF21 overexpression alleviates VSMC senescence in diabetic mice by modulating the SYK-NLRP3 inflammasome-PPARgamma-catalase pathway","volume":"56","author":"Heng","year":"2024","journal-title":"Acta Biochim Biophys Sin Shanghai"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41374-021-00680-9","article-title":"Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice","volume":"102","author":"Yano","year":"2022","journal-title":"Lab Investig"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1168047","DOI":"10.3389\/fcvm.2023.1168047","article-title":"Fibroblast growth factor 21 resistance is associated with body shape in patients with type 2 diabetes complicating hypertension","volume":"10","author":"Gan","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1007\/s11357-024-01463-y","article-title":"ADAM10-mediated beta-klotho degradation: a key to FGF21 resistance in senescent vascular endothelial cells","volume":"47","author":"Huang","year":"2025","journal-title":"Geroscience"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.2337\/db07-1476","article-title":"Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans","volume":"57","author":"Zhang","year":"2008","journal-title":"Diabetes"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/6777771","article-title":"Relationship between serum FGF21 and vWF expression and carotid atherosclerosis in elderly patients with hypertension","volume":"2022","author":"Bian","year":"2022","journal-title":"J Healthc Eng"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11154-019-09488-x","article-title":"The roles of FGF21 in atherosclerosis pathogenesis","volume":"20","author":"Tabari","year":"2019","journal-title":"Rev Endocr Metab Disord"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.7150\/ijbs.73936","article-title":"Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine","volume":"19","author":"Tan","year":"2023","journal-title":"Int J Biol Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1108234","DOI":"10.3389\/fendo.2023.1108234","article-title":"Fibroblast growth factor 21 and prognosis of patients with cardiovascular disease: a meta-analysis","volume":"14","author":"Yan","year":"2023","journal-title":"Front Endocrinol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e51924","DOI":"10.7759\/cureus.51924","article-title":"The correlation between serum fibroblast growth factor 21 and the severity and occurrence of coronary artery disease","volume":"16","author":"Sinha","year":"2024","journal-title":"Cureus"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12902-023-01523-y","article-title":"Increased circulating FGF21 level predicts the burden of metabolic demands and risk of vascular diseases in adults with type 2 diabetes","volume":"23","author":"Liu","year":"2023","journal-title":"BMC Endocr Disord"},{"key":"ref32","first-page":"643","article-title":"A standardized method for measuring intracranial arterial stenosis","volume":"21","author":"Samuels","year":"2000","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1056\/NEJMoa2508800","article-title":"Medical management and revascularization for asymptomatic carotid stenosis","volume":"394","author":"Brott","year":"2026","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"III","DOI":"10.1177\/23969873221099715","article-title":"European stroke organisation guidelines on treatment of patients with intracranial atherosclerotic disease","volume":"7","author":"Psychogios","year":"2022","journal-title":"Eur Stroke J"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10072-019-04105-w","article-title":"Concomitant diabetes or hypertension with metabolic syndrome on the extent of intracranial atherosclerotic stenosis","volume":"41","author":"Park","year":"2020","journal-title":"Neurol Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1161\/ATVBAHA.113.301599","article-title":"Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors","volume":"33","author":"Chow","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3346\/jkms.2015.30.5.586","article-title":"Association between serum fibroblast growth factor 21 and coronary artery disease in patients with type 2 diabetes","volume":"30","author":"Kim","year":"2015","journal-title":"J Korean Med Sci"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"0815","DOI":"10.34133\/research.0815","article-title":"Fibroblast growth factor 21 promotes vascular smooth muscle cell contractile polarization via p38 mitogen-activated protein kinase-promoted serum response factor phosphorylation","volume":"8","author":"Zhu","year":"2025","journal-title":"Research"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e040460","DOI":"10.1161\/JAHA.124.040460","article-title":"Circulating markers of inflammation and endothelial dysfunction associated with increased progression of internal carotid intima-media thickness in the population-based Framingham heart study","volume":"14","author":"Baradaran","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1159\/000363031","article-title":"Fibroblast growth factor 21 protects against high glucose induced cellular damage and dysfunction of endothelial nitric-oxide synthase in endothelial cells","volume":"34","author":"Wang","year":"2014","journal-title":"Cell Physiol Biochem"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41419-019-1893-6","article-title":"Fibroblast growth factor 21 ameliorates diabetes-induced endothelial dysfunction in mouse aorta via activation of the CaMKK2\/AMPKalpha signaling pathway","volume":"10","author":"Ying","year":"2019","journal-title":"Cell Death Dis"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"178224","DOI":"10.1016\/j.ejphar.2025.178224","article-title":"FGF21 alleviates diabetic vasculopathy with NF-kappaB suppression and fibrinolytic activation","volume":"1007","author":"Li","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2147\/NDT.S504180","article-title":"Fibroblast growth factor 21 protects against cerebral ischemia\/reperfusion injury by inhibiting oxidative stress and Ferroptosis","volume":"21","author":"Li","year":"2025","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e18308","DOI":"10.7717\/peerj.18308","article-title":"The association between fibroblast growth factor 21 with diabetes retinopathy among type 2 diabetes mellitus patients: a systematic review, meta-analysis, and meta-regression","volume":"12","author":"Basir","year":"2024","journal-title":"PeerJ"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1904036\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T04:23:46Z","timestamp":1788755026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1904036\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":44,"alternative-id":["10.3389\/fneur.2026.1904036"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1904036","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"1904036"}}